Posted January 06, 2018 06:21:17 The next big thing in Northwestern Medicine andrology is now a thing.
The Journal of andrology has published an article on the latest research into the development of menopause symptoms and their treatment.
AndroloGE Berlin, the journal of Andrologics, reports that a team of researchers from the Universities of Tübingen and Berlin have developed a new test for measuring levels of testosterone and estradiol in menopausal women.
They hope to be able to use this test to assess the need for hormone replacement therapy.
Andrologist Martin Sauer, the lead author of the paper and a clinical professor of dermatology at the Berlin Institute for Advanced Studies, says the test is particularly important in the treatment of menopausal symptoms in the female patient.
The test measures the concentration of the steroid hormone testosterone and the amount of estrogen in the blood.
“The testosterone concentration in the women was higher than the female serum concentration and the estrogen level was higher,” Sauer told Newsweek.
“In fact, the concentration was higher in the estrogen-containing urine than in the testosterone-containing serum.
This indicates that the women are receiving estrogen, which causes an increase in testosterone levels in the body, whereas the male serum concentration is not high enough.”
The new test was developed by a group of researchers at the Institute for Clinical Chemistry of the University of TÜbingen, and the University’s Department of Medicine and Science.
Andrology is a branch of medicine concerned with the physiological changes that take place in the human body during periods of manhood.
Androgen levels in women have a significant impact on their physical appearance, as well as their reproductive and sexual development.
In the United States, about 20% of women over 50 are currently taking androgen replacement therapy (ART).
But the treatment has serious side effects for both men and women, and for women over 65 it can cause bone loss, and can lead to increased risk of breast cancer.
Sauer’s research group has been working on a testosterone-to-estradiol test for menopausal patients for over 10 years.
The results of his testing has been published in the European Journal of Endocrinology.
And the researchers believe the test will be a breakthrough in treating menopausal menopausis.
Sabor, who is also the author of more than 40 books and two books of medical journals, said he was motivated to do the research because “there are so many patients who suffer from this androgens and the treatment is so expensive, it’s not feasible for a woman to afford.”
Andrological researchers at TÝbingen have published a number of studies on the treatment androgen therapy.
But Sauer is especially excited about the prospect of the testosterone to estradiosylstathionyl test.
And as an integrative androgen researcher, Sabor said the test could also help in the development and management of hormone therapy for men with prostate cancer.
He said he believes that the testosterone test could be used to predict whether men will develop prostate cancer within five years of receiving ART.
Säber added that he hopes to have a similar test in use in the coming years.